Core Viewpoint - Company has recovered part of the settlement amount of 85 million yuan after five years of issues with Anxin Trust, which significantly impacted its financial performance in the third quarter of the year [1] Financial Performance - For the first three quarters of the year, the company reported revenue of 1.208 billion yuan, a year-on-year decrease of 17.62%, primarily due to a decline in the export prices of raw material orders [1] - The net profit attributable to shareholders reached 310 million yuan, a year-on-year increase of 56.47%, mainly due to improved gross profit margins and the recovery of part of the bad debt provision from Anxin Trust [1] - In the third quarter, the company achieved revenue of 352 million yuan, a year-on-year decrease of 13.97%, while the net profit attributable to shareholders was 127 million yuan, a year-on-year increase of 60.84% [1] Settlement with Anxin Trust - The company reached a settlement with Jianyuan Trust regarding the Ruiying 64 Trust Plan, receiving 85 million yuan, which is 50% of the principal amount of 170 million yuan [1] - The company has submitted a withdrawal application to the Shanghai Financial Court regarding the case, and the court has approved the withdrawal [1] - The 85 million yuan settlement contributed approximately 67% of the company's net profit in the third quarter [1] Acquisition of Fangyuan Pharmaceutical - The company has signed an agreement to participate in the bankruptcy reorganization of Fangyuan Pharmaceutical, planning to acquire 100% of its equity for 390 million yuan [3] - The reorganization will retain Fangyuan Pharmaceutical's legal entity status while separating non-restructurable assets [3] - Fangyuan Pharmaceutical's core product, Sulbactam, is a new generation semi-synthetic aminoglycoside antibiotic with significant market potential and limited competition [3]
“踩雷”安信信托5年后 千红制药收回部分和解款